Responses to Subsequent Anti-HER2 Therapy after Treatment with Trastuzumab-DM1 in Women with HER2-Positive Metastatic Breast Cancer

被引：0
|
作者：
Olson, E. M. [1 ]
Lin, N. U. [1 ]
DiPiro, P. J. [1 ]
Najita, J. [1 ]
Krop, I. E. [1 ]
Winer, E. P. [1 ]
Burstein, H. J. [1 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
CANCER RESEARCH | 2010年 / 70卷
关键词：
D O I：
10.1158/0008-5472.SABCS10-P3-14-08
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3-14-08
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Responses to subsequent anti-HER2 therapy after treatment with trastuzumab-DM1 in women with HER2-positive metastatic breast cancer
    Olson, E. M.
    Lin, N. U.
    DiPiro, P. J.
    Najita, J. S.
    Krop, I. E.
    Winer, E. P.
    Burstein, H. J.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 (01) : 93 - 97
  • [2] Anti-HER2 therapy for HER2-positive metastatic breast cancer: regimens and treatment outcomes
    Watanabe, Kenichi
    Hagio, Kanako
    Baba, Motoi
    Ikarashi, Mayuko
    Sato, Masako
    Tomioka, Nobumoto
    Takahashi, Masato
    [J]. ANNALS OF ONCOLOGY, 2015, 26 : 143 - 143
  • [3] HER2-positive breast cancer: From trastuzumab to innovatory anti-HER2 strategies
    Whenham, Nicolas
    D'Hondt, Veronique
    Piccart, Martine J.
    [J]. CLINICAL BREAST CANCER, 2008, 8 (01) : 38 - 49
  • [4] Trastuzumab therapy in HER2-positive, metastatic breast cancer
    Smith, A. D.
    Guilbert, K.
    Lister, D.
    Streilein, S.
    Bourrier, V. C.
    Lozar, B.
    Navaratnam, S.
    Harding, G. A.
    Pitz, M. W.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [5] Differential responses of HER2-positive breast cancer cells to anti-HER2 treatment.
    Yu, Rong
    Chiu, Kung Y.
    Shi, Lili
    Zhang, Peter
    Duan, Chun-Xiao
    Lu, Sunny
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [6] Handling of anti-HER2 antibodies, trastuzumab and pertuzumab, in patients with HER2-positive breast cancer
    Araki, Kazuhiro
    Ito, Yoshinori
    [J]. ANNALS OF ONCOLOGY, 2015, 26 : 48 - 48
  • [7] Trastuzumab: Anti-HER2 antibody for treatment of metastatic breast cancer
    Wong, WM
    [J]. CANCER PRACTICE, 1999, 7 (01) : 48 - 50
  • [8] TRASTUZUMAB EMTANSINE FOR THE TREATMENT OF HER2-POSITIVE METASTATIC BREAST CANCER
    Haddley, K.
    [J]. DRUGS OF TODAY, 2013, 49 (11) : 701 - 715
  • [9] Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer
    Barok, Mark
    Tanner, Minna
    Koninki, Katri
    Isola, Jorma
    [J]. CANCER LETTERS, 2011, 306 (02) : 171 - 179
  • [10] Margetuximab Anti-HER2 monoclonal antibody Treatment of metastatic HER2-positive breast cancer Treatment of HER2-positive gastric or gastroeso-phageal junction cancer
    Hanna, K. S.
    [J]. DRUGS OF THE FUTURE, 2021, 46 (03) : 191 - 195
12345